<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742491</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 091</org_study_id>
    <nct_id>NCT04742491</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis for Transgender Women in the US and South America</brief_title>
  <official_title>HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HIV Prevention Trials Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the feasibility, acceptability, and preliminary impact of a multi-component&#xD;
      strategy to improve pre-exposure prophylaxis (PrEP) uptake and adherence that integrates&#xD;
      delivery of biomedical HIV prevention co-located with gender-affirming transgender care&#xD;
      (hormonal therapy and medical monitoring) and Peer Health Navigation (PHN) using&#xD;
      Strengths-Based Case Management (SBCM) professional supervision.&#xD;
&#xD;
      Multi-site, open-label study with each participant randomized 1:1 to Immediate Intervention&#xD;
      vs. 6-month Deferred Intervention Arms. Both arms will be provided PrEP and sexually&#xD;
      transmitted infection (STI) screening and treatment. Participants in the Immediate&#xD;
      Intervention Arm will receive co-located gender-affirming medical care and PHN using SBCM&#xD;
      starting at the Enrollment Visit. Participants in the Deferred Intervention Arm will receive&#xD;
      linkage to external gender-affirming medical care and case management services during the&#xD;
      deferred period and will transition to the study intervention six months following the&#xD;
      Enrollment Visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      entered elsewhere&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">November 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Intermediate Intervention Arm vs Deferred Intervention Arm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uptake of hormonal therapy and PrEP</measure>
    <time_frame>0-36 months</time_frame>
    <description>Strengths-based case management to measure amount of PrEP uptake and gender affirming hormonal therapy uptake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PrEP adherence and persistence</measure>
    <time_frame>0-36 months</time_frame>
    <description>Measure of amount of drug taken via self reported pill count and biological markers via plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV incidence</measure>
    <time_frame>0-36 months</time_frame>
    <description>Measured via 4th generation ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STI incidence</measure>
    <time_frame>0-36 months</time_frame>
    <description>GC/chlamydial and syphilis laboratory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sexual risk taking behavior</measure>
    <time_frame>0-36 months</time_frame>
    <description>Self report number of partners, serostatus and number/type of acts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of baseline lab data for suitability of this population for future PrEP research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Hepatitis B status via antibody, antigen and core antibody testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of baseline lab data for suitability of this population for future PrEP research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Hepatitis C testing via antibody testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of baseline lab data for suitability of this population for future PrEP research</measure>
    <time_frame>0-36 months</time_frame>
    <description>serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of baseline lab data for suitability of this population for future PrEP research</measure>
    <time_frame>0-36 months</time_frame>
    <description>urine for STI testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of baseline lab data for suitability of this population for future PrEP research</measure>
    <time_frame>0-36 months</time_frame>
    <description>NAAT for rectal and pharyngeal swabs for STI testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological factors tied to PreP uptake, adherence, persistence, interest in future HIV research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Self-administered questionnaire; o Depression via PHQ2: Scale 0-6, score 3 or higher is positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>behavioral alcohol use factors tied to PreP uptake, adherence, persistence, interest in future HIV research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Self-administered questionnaire; o Alcohol use via AUDIT-C: Scale 0-12 points. Score &gt; 4 is positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>behavioral substance use factors tied to PreP uptake, adherence, persistence, interest in future HIV research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Self-administered questionnaire; o Substance use via CAGE-AID: Scale 0-4. Score &gt;2 is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PrEP uptake, adherence, persistence and interest in future HIV research</measure>
    <time_frame>0-36 months</time_frame>
    <description>Self-administered questionnaire (no scale)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Immediate Intervention Arm Descovy in the US</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Intervention Arm Descovy in the US</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Intervention Arm Truvada in Brazil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Intervention Arm Truvada in Brazil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Intervention Arm Truvada in the US</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Intervention Arm Truvada in the US</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Intervention Arm Truvada in the US</intervention_name>
    <description>Truvada in the United States</description>
    <arm_group_label>Immediate Intervention Arm Truvada in the US</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferred Intervention Arm Truvada in the US</intervention_name>
    <description>Truvada in the United States</description>
    <arm_group_label>Deferred Intervention Arm Truvada in the US</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Intervention Arm Truvada in Brazil</intervention_name>
    <description>Truvada in Brazil</description>
    <arm_group_label>Immediate Intervention Arm Truvada in Brazil</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferred Intervention Arm Truvada in Brazil</intervention_name>
    <description>Truvada in Brazil</description>
    <arm_group_label>Deferred Intervention Arm Truvada in Brazil</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Intervention Arm Descovy in the US</intervention_name>
    <description>Descovy in the United States</description>
    <arm_group_label>Immediate Intervention Arm Descovy in the US</arm_group_label>
    <other_name>Descovy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferred Intervention Arm Descovy in the US</intervention_name>
    <description>Descovy in the United States</description>
    <arm_group_label>Deferred Intervention Arm Descovy in the US</arm_group_label>
    <other_name>Descovy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TGW (assigned male at birth, trans-feminine spectrum - as defined in the SSP Manual -&#xD;
             by self-report) who meet all of the following criteria are eligible for inclusion in&#xD;
             this study.&#xD;
&#xD;
          -  Eighteen years or older at the time of screening.&#xD;
&#xD;
          -  Willing and able to provide informed consent for the study.&#xD;
&#xD;
          -  Interest in PrEP - as defined in the SSP Manual.&#xD;
&#xD;
          -  Non-reactive HIV test results at Screening and Enrollment.&#xD;
&#xD;
          -  Available to return for all study visits and within site catchment area, as defined&#xD;
             per site's Standard Operating Procedures (SOP).&#xD;
&#xD;
          -  At risk for sexually acquiring HIV infection based on self-report of at least one of&#xD;
             the following:&#xD;
&#xD;
               1. Any anal or vaginal sex with one or more serodiscordant or HIV-unknown serostatus&#xD;
                  sexual partners in the previous 3 months, regardless of condom use.&#xD;
&#xD;
               2. Anal or vaginal sex in exchange for money, food, shelter, or other goods or&#xD;
                  favors in the previous 3 months.&#xD;
&#xD;
               3. History of STI(s) in the past 6 months.&#xD;
&#xD;
          -  Willing to undergo all required study procedures.&#xD;
&#xD;
          -  General good health, as evidenced by the following laboratory values:&#xD;
&#xD;
               1. Calculated creatinine clearance ≥ 60 mL/minute using the Cockcroft-Gault&#xD;
                  equation.&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 times&#xD;
                  the upper limit of normal (ULN.)&#xD;
&#xD;
               3. HBV surface antigen (HBsAg) negative.&#xD;
&#xD;
        Note: Otherwise eligible participants with laboratory results outside the above-mentioned&#xD;
        values, with the exception of those with reactive HIV test, can be re-tested during the&#xD;
        screening window. Participants with reactive HIV tests will not be able to rescreen.&#xD;
&#xD;
        Note: Participants who practice receptive vaginal sex cannot be provided Descovy® as it is&#xD;
        not approved for this indication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any reactive or positive HIV test result at Screening or Enrollment, even if HIV&#xD;
             infection is not confirmed.&#xD;
&#xD;
          2. Plans to move away from the site area within the next 18 months.&#xD;
&#xD;
          3. Co-enrollment in any other research study that may interfere with this study (as&#xD;
             provided by self-report or other available documentation). Exceptions may be made&#xD;
             after consultation with the Clinical Management Committee (CMC).&#xD;
&#xD;
          4. Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic&#xD;
             steatohepatitis) or known hepatic or biliary abnormalities (with the exception of&#xD;
             Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy).&#xD;
&#xD;
          5. History of deep vein thrombosis, pulmonary embolism, and/or clotting disorder.&#xD;
&#xD;
          6. Active or planned use of medications with significant drug interactions as described&#xD;
             in the Package Insert for Truvada® or Descovy®, per clinician's discretion (provided&#xD;
             by selfreport or obtained from medical history or medical records). See Section 5.8&#xD;
             for a full list of drug interactions.&#xD;
&#xD;
          7. Any other condition, including but not limited to alcohol or substance abuse and&#xD;
             uncontrolled medical condition and/or allergies, that, in the opinion of the&#xD;
             Investigator of Record (IoR)/designee, would preclude informed consent, make study&#xD;
             participation unsafe, complicate interpretation of study outcome data, or otherwise&#xD;
             interfere with achieving the study objectives would make the patient unsuitable for&#xD;
             the study or unable/unwilling to comply with the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tonia Poteat, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bridge HIV CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Prevention Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinicaq Evandro Chagas CRS</name>
      <address>
        <city>Manguinhos</city>
        <state>RJ</state>
        <zip>221045-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transgender women</keyword>
  <keyword>TGW</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT04742491/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

